Literature DB >> 24805859

BCOR-CCNB3 (Ewing-like) sarcoma: a clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma.

Florian Puls1, Angela Niblett, Gillian Marland, Czar Louie L Gaston, Hassan Douis, D Chas Mangham, Vaiyapuri P Sumathi, Lars-Gunnar Kindblom.   

Abstract

BCOR-CCNB3 fusion transcripts resulting from an X-chromosomal paracentric inversion were recently identified in a series of unclassifiable soft tissue and bone sarcomas with Ewing sarcoma-like morphology. The morphologic and clinical features of these sarcomas are, as yet, not well characterized. Here we describe the clinicopathologic features of 10 cases of BCOR-CCNB3 sarcoma and compare their clinical course with typical Ewing sarcoma. Nine of 10 patients were male, and all were 11 to 18 years of age. Seven tumors were located in the bone and 3 in the deep soft tissues. The histomorphologic spectrum was quite wide, with 7 tumors predominately showing small primitive cell morphology with angulated nuclei simulating so-called atypical Ewing sarcoma and 3 predominately showing spindle cell morphology. Recurrent and metastatic lesions showed increased cellularity and marked pleomorphism. Immunohistochemistry showed expression of CCNB3 (100%), bcl2 (90%), CD99 (60%), and CD117 (60%). Reverse transcription polymerase chain reaction for BCOR-CCNB3 fusion transcripts was positive in all 9 cases, which yielded sufficient extracted RNA. Five- and 10-year survival rates were 75% and 56%, respectively. BCOR-CCNB3 sarcomas located in axial skeleton and soft tissues showed a significantly shorter survival. The Ewing sarcoma overall survival was not statistically different, although there was a trend for longer survival of patients with BCOR-CCNB3 sarcomas in the extremities. In conclusion, this study provides a detailed description of the histologic spectrum, immunohistochemical features, and clinical characteristic of BCOR-CCNB3 sarcoma justifying distinction from Ewing sarcoma with its typical EWS/FUS-ETS translocations. Ideally immunohistochemistry is used in combination with reverse transcription polymerase chain reaction for definitive diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24805859     DOI: 10.1097/PAS.0000000000000223

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

1.  Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH.

Authors:  Sonja Chen; Kemal Deniz; Yun-Shao Sung; Lei Zhang; Sarah Dry; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2015-12-22       Impact factor: 5.006

2.  Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas.

Authors:  Katja Specht; Lei Zhang; Yun-Shao Sung; Marisa Nucci; Sarah Dry; Sumathi Vaiyapuri; Gunther H S Richter; Christopher D M Fletcher; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

3.  Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes.

Authors:  Yuichi Yamada; Masaaki Kuda; Kenichi Kohashi; Hidetaka Yamamoto; Junkichi Takemoto; Takeaki Ishii; Kunio Iura; Akira Maekawa; Hirofumi Bekki; Takamichi Ito; Hiroshi Otsuka; Makoto Kuroda; Yumi Honda; Shinji Sumiyoshi; Takeshi Inoue; Naoe Kinoshita; Atsushi Nishida; Kyoko Yamashita; Ichiro Ito; Shizuo Komune; Tomoaki Taguchi; Yukihide Iwamoto; Yoshinao Oda
Journal:  Virchows Arch       Date:  2017-02-14       Impact factor: 4.064

4.  Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1-SS18 gene fusion.

Authors:  Abdullah Alholle; Marie Karanian; Anna T Brini; Mark R Morris; Vinodh Kannappan; Stefania Niada; Angela Niblett; Dominique Ranchère-Vince; Daniel Pissaloux; Christophe Delfour; Aurelie Maran-Gonzalez; Cristina R Antonescu; Vaiyapuri Sumathi; Franck Tirode; Farida Latif
Journal:  J Pathol       Date:  2018-04-16       Impact factor: 7.996

5.  BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas.

Authors:  Yu-Chien Kao; Adepitan A Owosho; Yun-Shao Sung; Lei Zhang; Yumi Fujisawa; Jen-Chieh Lee; Leonard Wexler; Pedram Argani; David Swanson; Brendan C Dickson; Christopher D M Fletcher; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-05       Impact factor: 6.394

6.  Molecular Approaches to Diagnosis in Ewing Sarcoma: Fluorescence In Situ Hybridization (FISH).

Authors:  Marcel Trautmann; Wolfgang Hartmann
Journal:  Methods Mol Biol       Date:  2021

7.  BCOR-CCNB3 fusion and BCOR internal tandem duplication in undifferentiated round cell sarcoma: a pathologic and molecular study of 5 cases.

Authors:  Yang Yang; Huijuan Shi; Jiaxin Zheng; Huabin Gao; Tiantian Zhen; Fenfen Zhang; Anjia Han
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

8.  Primary Renal Sarcomas With BCOR-CCNB3 Gene Fusion: A Report of 2 Cases Showing Histologic Overlap With Clear Cell Sarcoma of Kidney, Suggesting Further Link Between BCOR-related Sarcomas of the Kidney and Soft Tissues.

Authors:  Pedram Argani; Yu-Chien Kao; Lei Zhang; Carlos Bacchi; Andres Matoso; Rita Alaggio; Jonathan I Epstein; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-12       Impact factor: 6.394

Review 9.  New fusion sarcomas: histopathology and clinical significance of selected entities.

Authors:  Markku Miettinen; Anna Felisiak-Golabek; Alejandro Luiña Contreras; John Glod; Rosandra N Kaplan; Jonathan Keith Killian; Jerzy Lasota
Journal:  Hum Pathol       Date:  2019-01-08       Impact factor: 3.466

Review 10.  Ewing sarcoma and Ewing-like tumors.

Authors:  Marta Sbaraglia; Alberto Righi; Marco Gambarotti; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2019-12-04       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.